Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 466

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 466
---
 and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December 31, 2024 and 2023, the Company had ending balances of accrued royalty payables of $ 0.1million and $ 5.0thousand, respectively, which was recorded as accrued expenses under current liabilities on F-20

the consolidated balance sheets. During the years ended December 31, 2024 and 2023, the Company made royalty payments in the amount of $ 0.3million and $ 26.0thousand, respectively. As of December 31, 2024, nosales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement.

4. Fair Value Measurements

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):

|                                          |     | December 31, 2024 |        |     |                                        |   |     |                                            |   |     |                                         |        |
|:-----------------------------------------|:----|:------------------|-------:|:----|:---------------------------------------|:--|:----|:-------------------------------------------|:--|:----|:----------------------------------------|-------:|
|                                          |     | Balance           |        |     | Quoted Pricesin ActiveMarkets(Level 1) |   |     | SignificantOtherObservableInputs (Level 2) |   |     | SignificantUnobservableInputs (Level 3) |        |
| Liabilities                              |     |                   |        |     |                                        |   |     |                                            |   |     |                                         |        |
| Oramed Note                              |     | $                 | 12,161 |     | $                                      | — |     | $                                          | — |     | $                                       | 12,161 |
| Tranche B Notes                          |     |                   | 23,560 |     |                                        | — |     |                                            | — |     |                                         | 23,560 |
| Purchased Revenue Liability              |     |                   |  6,800 |     |                                        | — |     |                                            | — |     |                                         |  6,800 |
| Derivative liabilities